Evidence map›Paper›PMID 27275462›Full record

ArticleHepatobiliary surgery and nutrition2016

Ophthalmological side effects of interferon therapy of chronic hepatitis C.

Eman Medhat, Gamal Esmat, Eman Hamza, Amr Abdel Aziz, Waleed Fouad Fathalah, Samar Kamal Darweesh, Zeinab Zakaria, Sameh Mostafa

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatobiliary surgery and nutrition, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Eman Medhat1 Endemic Medicine and Hepato-gastroenterology, Faculty of Medicine, Cairo University, Egypt ; 2 Research Institute of Ophthalmology, Egypt.
Gamal Esmat1 Endemic Medicine and Hepato-gastroenterology, Faculty of Medicine, Cairo University, Egypt ; 2 Research Institute of Ophthalmology, Egypt.
Eman Hamza1 Endemic Medicine and Hepato-gastroenterology, Faculty of Medicine, Cairo University, Egypt ; 2 Research Institute of Ophthalmology, Egypt.
Amr Abdel Aziz1 Endemic Medicine and Hepato-gastroenterology, Faculty of Medicine, Cairo University, Egypt ; 2 Research Institute of Ophthalmology, Egypt.
Waleed Fouad Fathalah1 Endemic Medicine and Hepato-gastroenterology, Faculty of Medicine, Cairo University, Egypt ; 2 Research Institute of Ophthalmology, Egypt.
Samar Kamal Darweesh1 Endemic Medicine and Hepato-gastroenterology, Faculty of Medicine, Cairo University, Egypt ; 2 Research Institute of Ophthalmology, Egypt.
Zeinab Zakaria1 Endemic Medicine and Hepato-gastroenterology, Faculty of Medicine, Cairo University, Egypt ; 2 Research Institute of Ophthalmology, Egypt.
Sameh Mostafa1 Endemic Medicine and Hepato-gastroenterology, Faculty of Medicine, Cairo University, Egypt ; 2 Research Institute of Ophthalmology, Egypt.
Cairo University · EGResearch Institute of Ophthalmology · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEgypt has one of the highest prevalence of hepatitis C virus (HCV) worldwide. Ophthalmological side effects are recognized complications of interferon (IFN) therapy. This study aimed to evaluate IFN-induced ophthalmological manifestations in patients receiving PEGylated interferon (PEG IFN) and ribavirin (RBV) and to assess the effect of IFN duration, response and systemic risk factors on the severity.

methodsWe retrospectively analyzed 100 patients with chronic HCV who were candidates for PEG-IFN and RBV therapy. All patients were subjected to clinical and ophthalmological examination, laboratory investigations, abdominal ultrasound, colored fundus photography and fundus fluorescein angiography, follow up was made at weeks 12, 24, and 48 of treatment.

resultsIFN-induced retinopathy had been found in (9/100; 9%), 5 (5/9; 55.5%) of them had bilateral lesions, (3/9; 33.3%) were treatment responders and (6/9; 66.6%) non responders. The time of retinopathy appearance was mainly at W12. Retinopathy was asymptomatic in most of the affected patients (7/9; 77.77%) and reversible, cotton wool spots was the major associated sign. Patients with older age, DM and or HTN, and non-responders to antiviral therapy were associated with more severe retinopathy.

conclusionsRetinopathy is not a rare complication of IFN therapy for chronic HCV infection, but fortunately it's asymptomatic and reversible. Ophthalmological assessment at base-line and at follow up during IFN treatment is very important.

Indexed as

fundus fluorescein angiographyHepatitis C virus (HCV)interferon (IFN)retinopathy

Identifiers

PMID27275462
PMCPMC4876243
OpenAlexW2299487985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.